VRTXVertex Pharmaceuticals Incorporated

$125B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+62.0% YoY

Gross Profit

$1.3B87.9% margin

Operating Income

$718M47.1% margin

Net Income

$837M54.9% margin

EPS (Diluted)

$3.18

QoQ Revenue Growth

+0.6%

Cash Flow

Operating Cash Flow

$1.0B

Free Cash Flow

$1.0B

Stock-Based Comp.

$117M

Balance Sheet

Total Assets

$10.2B

Total Liabilities

$2.7B

Stockholders' Equity

$7.5B

Cash & Equivalents

$4.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$941M	+62.0%
Gross Profit	$1.3B	$806M	+66.3%
Operating Income	$718M	$270M	+166.0%
Net Income	$837M	$267M	+213.1%

Revenue Segments

TRIKAFTA/KAFTRIO

$918M60%

ORKAMBI

$232M15%

KALYDECO

$203M13%

SYMDEKO/SYMKEVI

$172M11%

Geographic Segments

UNITED STATES

$1.2B79%

Europe

$258M17%

Other, Non U.S.

$56M4%

VRTX Q2 2020 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena